HDAC9 and breast carcinoma: As a consequence, the employment of nuclear CPT1A “cancer specific” variant 2 as a target for new anticancer therapeutics could activate cancer-relevant death genes by epigenetic regulation, in a more selective and specific manner as compared to other known HDAC inhibitors, representing an attractive and concrete opportunity to improve current strategies for breast cancer therapy.